Nodularis – Socially Bharat

socially bharat
December 13, 2024
12 Mins Read

CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union

Zug, Switzerland: Atopic dermatitis is a common, chronic, and flaring inflammatory skin disease characterized by persistent itch and recurrent

54 Views
0 Comments

READ MORE

socially bharat
November 29, 2024
9 Mins Read

Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis

Zug, Switzerland: Full results from the phase III OLYMPIA 1 trial evaluating the efficacy and safety of nemolizumab in

55 Views
0 Comments

READ MORE

socially bharat
September 25, 2024
9 Mins Read

New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations

Zug, Switzerland: New 56-week data from an interim analysis of the phase III ARCADIA long-term extension study will be

53 Views
0 Comments

READ MORE

Socially Bharat is your comprehensive source for Social news, NGO’s, and expert insights from across India.

Quick Links

Contact Us

Stay Updated

Share Your Message!

Copyright© 2025 Creative Bharat Powered By A Buzz Company